Close

News

Vanda reports positive data of tasimelteon in Non-24-Hour Disorder

Vanda Pharmaceuticals' tasimelteon has shown the ability to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder). Tasimelteon is a circadian...

Prosensa secures financing to develop RNA-modulating therapeutics

Dutch-based biopharmaceutical company, Prosensa has raised €23m in new equity financing to advance its portfolio of RNA-modulating therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington's disease (HD). ...

Selventa receives new patent for discovery of biomarker profiles

Selventa, a biomarker discovery company, has received US patent entitled Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems. The patent is related to methods and techniques that facilitate discovery of biomarkers and aid in the...

Upsher-Smith launches new prenatal vitamin

Upsher-Smith Laboratories has launched B-Nexa, a prescription prenatal vitamin for pregnant women who suffer from nausea and vomiting of pregnancy (NVP). B-Nexa is designed with B vitamins and ginger to help calm NVP, also...

Merck will pay a maximum of $37 million to settle all claims against its painkiller Vioxx in Canada.

The settlement includes $10 million in costs and fees, and will total between $21.8 million and $37 million, depending upon the number of eligible claims. The plaintiffs’ lawyer Mike Peerless said up to 2,000 Canadians...

BTG receives US Voraxaze approval

UK-based pharmaceutical company BTG has received US Food and Drug Adminsitration (FDA) approval for its Voraxaze medication, which is used to treat patients suffering from toxic levels of methotrexate due to kidney failure. The basis of the approval...

AstraZeneca and Bristol-Myers Squibb diabetes drug rejected by FDA

Approval for AstraZeneca and Bristol-Myers Squibb's diabetes drug dapagliflozin has been rejected by the US Food and Drug Administration. The FDA issued the rejection in its complete response letter, stating that additional clinical data...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »